New Classifications of Five Distinct “Sleep” Profi... ...
Science in the Age of AI | AI for Science Forum...
Ask the Heart Doctor | Heart Valve Disease and Sur...
High-speed imaging tracks live brain cell activity...
NAD⁺ restores memory in Alzheimer's disease models...
Mark Cuban: A Master Disrupter for American Health...
Teen girls facing the most adversity showed the biggest gain...
September 15,2026
Specialized imaging reveals hormone-driven brain changes...
September 14,2026
Submillimeter MRI reveals brain hubs that guide risky decisi...
September 12,2026
Risk of herpes zoster among breast cancer survivors in Japan...
September 11,2026
Three proteins help organs tailor shared circadian clock to ...
September 10,2026
Should you worry about melatonin and heart failure? The evid...
December 02,2025
Category
Traditional Medicine
Q & A
Wellness
Drug Discovery
Technology & AI
Clinical Pearl Series
Breakthroughs
Immunology & Rheumatology
Reproduction
Hepatobiliary&Pancreas Surgery
Most Read
Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and SexAverage Ranges Show Normal Pressure On the ArteriesBySheryl Huggins SalomonUpdated on April 21, 2023Medically reviewed byJeffre
Cardiovascular Diseases April 07,2024
Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and SexAverage Ranges Show Normal Pressure On the ArteriesBySheryl Huggins SalomonUpdated on April 21, 2023Medically reviewed byJeffre
Cardiovascular Diseases April 07,2024
Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals has commenced dosing the first patients in its Phase 2a clinical trial for PP405, a novel topical treatment designed to reactivate dormant hair follicle stem cells.
Dermatology August 14,2024
Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals has commenced dosing the first patients in its Phase 2a clinical trial for PP405, a novel topical treatment designed to reactivate dormant hair follicle stem cells.
Dermatology August 14,2024
Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs MeanWhat to Know About Your Blood TypeByNancy LeBrunPublished on September 15, 2023Medically reviewed byAnju Goel, MDYou
Oncology March 17,2024
Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs MeanWhat to Know About Your Blood TypeByNancy LeBrunPublished on September 15, 2023Medically reviewed byAnju Goel, MDYou
Oncology March 17,2024
Today's News
GOSH BRC Showcase 2025 - Genomic medicine...
Can a twice-a-year shot help end the HIV...
Announcement of the 2025 Nobel Prize in ...
Reprogramming Stem Cells Could Cure Type...
Why MDMA did NOT get FDA approval...
More News
Stem Cell Recipients Develop Robust Immunity Against SARS-CoV2 and Common Human Coronaviruses

Stem Cell Recipients Develop Robust Immunity Against SARS-CoV2 and Common Human Coronaviruses

February 8, 2021Kristie L. KahlFebruary 8, 2021 - These findings may have implications for patients with hematologic malignancies, suggesting the development of protective memory against SARS-CoV2 and
World medicine November 20,2023
Stem Cell Recipients Develop Robust Immunity Against SARS-CoV2 and Common Human Coronaviruses

Stem Cell Recipients Develop Robust Immunity Against SARS-CoV2 and Common Human Coronaviruses

February 8, 2021Kristie L. KahlFebruary 8, 2021 - These findings may have implications for patients with hematologic malignancies, suggesting the development of protective memory against SARS-CoV2 and
World medicine November 20,2023
Improved Induction Therapies Could Eliminate the Need for Transplant in Myeloma

Improved Induction Therapies Could Eliminate the Need for Transplant in Myeloma

September 16, 2020Hayley VirgilJeffrey Wolf, MD, discusses how induction therapies continue to improve the depth of response in patients with multiple myeloma and how it may be possible to eliminate t
World medicine November 20,2023
Improved Induction Therapies Could Eliminate the Need for Transplant in Myeloma

Improved Induction Therapies Could Eliminate the Need for Transplant in Myeloma

September 16, 2020Hayley VirgilJeffrey Wolf, MD, discusses how induction therapies continue to improve the depth of response in patients with multiple myeloma and how it may be possible to eliminate t
World medicine November 20,2023
Maintenance Daratumumab Improves PFS in Newly Diagnosed Transplant-Eligible Myeloma

Maintenance Daratumumab Improves PFS in Newly Diagnosed Transplant-Eligible Myeloma

October 22, 2020Gina MauroSingle-agent daratumumab as maintenance therapy improved progression-free survival compared with observation in patients with newly diagnosed multiple myeloma eligible for au
World medicine November 20,2023
Maintenance Daratumumab Improves PFS in Newly Diagnosed Transplant-Eligible Myeloma

Maintenance Daratumumab Improves PFS in Newly Diagnosed Transplant-Eligible Myeloma

October 22, 2020Gina MauroSingle-agent daratumumab as maintenance therapy improved progression-free survival compared with observation in patients with newly diagnosed multiple myeloma eligible for au
World medicine November 20,2023
Daratumumab Consolidation Appears Safe, Shows Encouraging Efficacy in Very Good Responders With Myeloma

Daratumumab Consolidation Appears Safe, Shows Encouraging Efficacy in Very Good Responders With Myeloma

April 9, 2021Kristi RosaDaratumumab appears to be safe when used as consolidation therapy in patients with multiple myeloma, even soon after autologous stem cell transplant, and the agent has also dem
World medicine November 20,2023
Daratumumab Consolidation Appears Safe, Shows Encouraging Efficacy in Very Good Responders With Myeloma

Daratumumab Consolidation Appears Safe, Shows Encouraging Efficacy in Very Good Responders With Myeloma

April 9, 2021Kristi RosaDaratumumab appears to be safe when used as consolidation therapy in patients with multiple myeloma, even soon after autologous stem cell transplant, and the agent has also dem
World medicine November 20,2023
Abatacept Reduces Graft Vs Host Disease, Prednisone Use Following Stem Cell Transplant

Abatacept Reduces Graft Vs Host Disease, Prednisone Use Following Stem Cell Transplant

April 24, 2022Jason HarrisAbatacept significantly reduced steroid-refractory chronic graft versus host disease and the use of prednisone following allogeneic hematopoietic stem cell transplantation.Ab
World medicine November 20,2023
Abatacept Reduces Graft Vs Host Disease, Prednisone Use Following Stem Cell Transplant

Abatacept Reduces Graft Vs Host Disease, Prednisone Use Following Stem Cell Transplant

April 24, 2022Jason HarrisAbatacept significantly reduced steroid-refractory chronic graft versus host disease and the use of prednisone following allogeneic hematopoietic stem cell transplantation.Ab
World medicine November 20,2023
Tisagenlecleucel Fails to Improve EFS in Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma

Tisagenlecleucel Fails to Improve EFS in Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma

December 14, 2021Jessica HergertAs second-line treatment, tisagenlecleucel failed to demonstrate an event-free survival advantage compared with standard of care platinum-based chemotherapy followed by
World medicine November 20,2023
Tisagenlecleucel Fails to Improve EFS in Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma

Tisagenlecleucel Fails to Improve EFS in Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma

December 14, 2021Jessica HergertAs second-line treatment, tisagenlecleucel failed to demonstrate an event-free survival advantage compared with standard of care platinum-based chemotherapy followed by
World medicine November 20,2023
Orca-T Graft Improves Outcomes in Myelofibrosis Following Allogeneic Stem Cell Transplant

Orca-T Graft Improves Outcomes in Myelofibrosis Following Allogeneic Stem Cell Transplant

February 4, 2022Gina MauroArpita Gandhi, MD, discusses a subgroup analysis of patients with myelofibrosis who received Orca-T and how this type of therapy could be a game-changer for this patient popu
World medicine November 20,2023
Orca-T Graft Improves Outcomes in Myelofibrosis Following Allogeneic Stem Cell Transplant

Orca-T Graft Improves Outcomes in Myelofibrosis Following Allogeneic Stem Cell Transplant

February 4, 2022Gina MauroArpita Gandhi, MD, discusses a subgroup analysis of patients with myelofibrosis who received Orca-T and how this type of therapy could be a game-changer for this patient popu
World medicine November 20,2023
John Theurer Cancer Center Investigators Confirm that Preserved Stem Cells Are Safe and Effective for Multiple Myeloma Treatment Up to 20 Years Later

John Theurer Cancer Center Investigators Confirm that Preserved Stem Cells Are Safe and Effective for Multiple Myeloma Treatment Up to 20 Years Later

April 21, 2022Hackensack Meridian John Theurer Cancer CenterInvestigators from Hackensack University Medical Center’s John Theurer Cancer Center confirm that cryopreserved stem cells collected before
World medicine November 20,2023
John Theurer Cancer Center Investigators Confirm that Preserved Stem Cells Are Safe and Effective for Multiple Myeloma Treatment Up to 20 Years Later

John Theurer Cancer Center Investigators Confirm that Preserved Stem Cells Are Safe and Effective for Multiple Myeloma Treatment Up to 20 Years Later

April 21, 2022Hackensack Meridian John Theurer Cancer CenterInvestigators from Hackensack University Medical Center’s John Theurer Cancer Center confirm that cryopreserved stem cells collected before
World medicine November 20,2023
Itolizumab May Minimize Incidence of aGVHD Following HSCT, Improve Outcomes

Itolizumab May Minimize Incidence of aGVHD Following HSCT, Improve Outcomes

December 16, 2021Chris RyanItolizumab showed the potential to decrease the response of host T cells to a donor graft, minimize the incidence of acute graft-vs-host disease following hematopoietic stem
World medicine November 20,2023
Itolizumab May Minimize Incidence of aGVHD Following HSCT, Improve Outcomes

Itolizumab May Minimize Incidence of aGVHD Following HSCT, Improve Outcomes

December 16, 2021Chris RyanItolizumab showed the potential to decrease the response of host T cells to a donor graft, minimize the incidence of acute graft-vs-host disease following hematopoietic stem
World medicine November 20,2023
Apamistamab Conditioning Treatment Induces High Rates of HCT Success in AML

Apamistamab Conditioning Treatment Induces High Rates of HCT Success in AML

February 11, 2021Lisa AstorFebruary 11, 2021 — Apamistamab conditioning treatment with targeted radioimmunotherapy to the bone marrow resulted in high rates of successful allogeneic hematopoietic stem
World medicine November 20,2023
Apamistamab Conditioning Treatment Induces High Rates of HCT Success in AML

Apamistamab Conditioning Treatment Induces High Rates of HCT Success in AML

February 11, 2021Lisa AstorFebruary 11, 2021 — Apamistamab conditioning treatment with targeted radioimmunotherapy to the bone marrow resulted in high rates of successful allogeneic hematopoietic stem
World medicine November 20,2023
More News
Week’s Top
Podcasts
... Health spending has been rising across rich countries with different systems ... ... GOSH BRC Showcase 2025 - Genomic medicine ... ... At what age do people experience depression for the first time? Depression can affect people over long periods of their lives. Some people experience this condition continuously, while for others, it occu...
FIND US ON
ABOUT
Who We Are
Contact Us
Editorial Team
Sitemap
Policy
Privacy Policy
Advertising Policy
Editorial Policy
Corrections Policy
Medical Disclaimer
Alliance
wmo.com
sleep.net
pharm.net
doctors.net
worldsleep.com